Two potentially dangerous anti-aging serums withdrawn from the market

The National Agency for the Safety of Medicines and Health Products (ANSM) has ordered the withdrawal of two potentially dangerous anti-aging sera from Laboratoire Promicea. Products considered by the agency as medicines and not cosmetics.

On Thursday, March 16, 2017, the National Agency for the Safety of Medicines and Health Products (ANSM) announced in a statement the withdrawal of the marketing of two anti-aging cosmetics products Laboratory Promicea NEOSTEM serum And NEOSTEM pocket lift, an eye contour.

The Agency considers that these products, "liable to present a danger to human health", do not meet the definition of a cosmetic, but of a medicinal product. As a result, they "were not subject, before marketing, to a marketing authorization", as must be the case for all medicinal products.

A composition deemed hazardous to health

The Promicea Laboratory claims the use of a combination of two molecules: sodium alendronate and pravastatin, a duo "capable of inhibiting the synthesis of a protein, progerin, the key molecule causing the disease Rare genetics of accelerated aging called Hutchinson-Gilford Syndrome or progéria ".

ANSM emphasizes the known toxic effects associated with the therapeutic uses of these components (neurological disorders, immune system disorder, gastrointestinal disorders, hepato-biliary disorders, musculoskeletal disorders, skin and subcutaneous tissue disorders, Stevens syndrome Johnson and toxic epidermal necrolysis, metabolic and nutritional disorders).

Read also

Toxic cosmetics list

Cosmetics and toxic substances: an update on these products

In conclusion, the agency considers that NEOSTEM serum and NEOSTEM pocket lift are potentially hazardous to health. It therefore requests the Promicea Laboratory to "suspend the manufacture, exportation, wholesale distribution, placing on the market free of charge or onerous, holding for sale or distribution free of charge and advertising" Of the two products in question "until they are brought into conformity with the rules of the medicinal product applicable to them."